Regeneron, Teva Report Positive Phase 3 Fasinumab Results
2018年8月16日 - 9:06PM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Teva Pharmaceutical
Industries Ltd. (TEVA) on Thursday said a Phase 3 study of
fasinumab in patients with chronic pain from osteoarthritis of the
knee or hip met both co-primary endpoints and all key secondary
endpoints.
The companies said fasinumab-treated patients experienced
significantly less pain and significantly improved functional
ability compared with placebo at the week-16 primary efficacy
analysis.
Regeneron and Teva are jointly developing fasinumab, an
investigational therapy invented by Regeneron, as part of a
collaboration agreement they reached in 2016, with Teva making a
$250 million upfront payment to Regeneron.
The Phase 3 study is a sub-study of a larger, long-term trial
that involves 52 weeks of active treatment, designed to determine
the safety and tolerability of fasinumab in pain from
osteoarthritis of the knee or hip.
The companies said interim safety data showed the drug was
generally well tolerated, with similar adverse events as those seen
in previous trials.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 16, 2018 07:51 ET (11:51 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024